Brolucizumab
Brolucizumab is an anti-VEGF antibody fragment injection used to treat certain eye conditions that cause vision loss. It works by blocking all three major isoforms of VEGF-A, a protein that promotes abnormal blood vessel growth and fluid leakage in the retina. This medication is administered by healthcare professionals as an intravitreal injection into the eye.
Brolucizumab is an eye injection that treats wet age-related macular degeneration and diabetic macular edema by blocking VEGF-A to reduce abnormal blood vessel growth and fluid buildup.
Key facts at a glance
- ATC
- S01LA06
- RxNorm
- 2204915
- Generic
- Brolucizumab
- Class
- atc-s01
- Brands
- Beovu
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection, prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 6mg once monthly for 3 months (loading phase), then 6mg every 12 weeks
- Maximum
- consult physician
- Frequency
- monthly loading, then every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not established
- Maximum
- consult physician
- Frequency
- not applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 6mg once monthly for 3 months (loading phase), then 6mg every 12 weeks
- Maximum
- consult physician
- Frequency
- monthly loading, then every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks to the fetus
regular fetal monitoring and ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
continue only if clearly needed for maternal vision preservation
fetal growth monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
consider deferring treatment until after delivery if clinically feasible
fetal monitoring and assessment of gestational age
Use with caution and monitor for adverse effects.
lactation
breastfeedingnot established
discontinue breastfeeding or discontinue drug, considering importance of drug to mother
monitor infant for any adverse effects
pediatric_age
pediatric 0 18not applicable
not indicated for use in pediatric patients; safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65no adjustment needed
no dose adjustment required; monitor for intraocular inflammation and retinal vascular occlusion
routine ophthalmologic monitoring
renal_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
standard monitoring
hepatic_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate hepatic impairment
standard monitoring
Statistics and clinical data
FDA approval year
FDA approval date for Brolucizumab (Beovu)
Drug class
Therapeutic class based on mechanism of action
Primary indication
Main therapeutic indication approved by regulatory authorities
Mechanism of action
Pharmacological mechanism of action
Brolucizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), conditions that can lead to vision loss if left untreated.
As a humanized single-chain antibody fragment, brolucizumab binds to VEGF-A isoforms (VEGF 110, VEGF 121, and VEGF 165), preventing them from interacting with VEGFR-1 and VEGFR-2 receptors. This inhibition suppresses endothelial cell proliferation and reduces vascular permeability, thereby decreasing abnormal blood vessel growth and fluid leakage in the retina.
Brolucizumab is administered as an intravitreal injection by a qualified healthcare professional. Common side effects may include conjunctival hemorrhage, eye pain, and vitreous floaters. Patients should be monitored for potential serious adverse events including endophthalmitis and retinal vasculitis. Regular eye examinations are required throughout treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy